NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,794.12 mln
1-Year Forecast
42.65
Transformational upside
Relative Strength
82
/ 100
Strongly outperforming
Debt / Equity
-0.03
Negative equity
ROE
-36.90
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Kailera Therapeutics is a clinical-stage company founded in 2024 and headquartered in Waltham, Massachusetts, focused on developing treatments for obesity and related metabolic conditions. Its pipeline includes both injectable and oral drug candidates at various stages of development, spanning small molecules and peptides. The company holds exclusive rights to develop and sell four metabolic disease treatments worldwide, excluding Greater China.
